Trial-Level Planned Duration of 2 Years vs. Indefinite Immunotherapy in Advanced NSCLC: A Systematic Review and Network Meta-Analysis

SSRN Electronic Journal 2026 Preprint Open access

Read full text

Authors: Jiamei YU, Qinger Ling, Yi Jiao, Siqi Ni, Tingyu Zhao, Xiao Zhang, Yali Jiang, Lijuan Meng, Lingxiang Liu

DOI: 10.2139/ssrn.6134919

Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Cancer Immunotherapy and Biomarkers